Is Verve Therapeutics Stock a Good Investment?
Verve Therapeutics Investment Advice | VERV |
- Examine Verve Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Verve Therapeutics' leadership team and their track record. Good management can help Verve Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Verve Therapeutics' business and its evolving consumer preferences.
- Compare Verve Therapeutics' performance and market position to its competitors. Analyze how Verve Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Verve Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Verve Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Verve Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Verve Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Verve Therapeutics Stock
Researching Verve Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.96. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Verve Therapeutics recorded a loss per share of 2.46. The entity had not issued any dividends in recent years.
To determine if Verve Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Verve Therapeutics' research are outlined below:
| Verve Therapeutics generated a negative expected return over the last 90 days | |
| Verve Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 11.76 M. Net Loss for the year was (200.07 M) with loss before overhead, payroll, taxes, and interest of (128.15 M). | |
| Verve Therapeutics currently holds about 293.56 M in cash with (149.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9. | |
| Over 98.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from investing.com: Verve Therapeutics SWOT analysis gene editing firms stock faces hurdles |
Verve Therapeutics Quarterly Cash And Short Term Investments |
|
Verve Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Verve Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Verve Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Verve Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Verve Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.6617 | -0.59 | 0.0717 | 10 | ||
2023-03-02 | 2022-12-31 | -0.76 | -0.67 | 0.09 | 11 | ||
2024-11-05 | 2024-09-30 | -0.6877 | -0.59 | 0.0977 | 14 | ||
2022-03-14 | 2021-12-31 | -0.55 | -0.65 | -0.1 | 18 | ||
2024-05-08 | 2024-03-31 | -0.71 | -0.59 | 0.12 | 16 | ||
2024-02-27 | 2023-12-31 | -0.82 | -0.69 | 0.13 | 15 | ||
2022-08-09 | 2022-06-30 | -0.65 | -0.84 | -0.19 | 29 | ||
2023-11-07 | 2023-09-30 | -0.92 | -0.72 | 0.2 | 21 |
Know Verve Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Verve Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Verve Therapeutics backward and forwards among themselves. Verve Therapeutics' institutional investor refers to the entity that pools money to purchase Verve Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2024-06-30 | 1.7 M | Geode Capital Management, Llc | 2024-09-30 | 1.6 M | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 1.6 M | Fmr Inc | 2024-09-30 | 1.4 M | Redmile Group, Llc | 2024-09-30 | 1.4 M | Goldman Sachs Group Inc | 2024-06-30 | 1.3 M | Ecor1 Capital, Llc | 2024-09-30 | 1.2 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.2 M | Nikko Asset Management Americas Inc | 2024-06-30 | 1.1 M | Alphabet Inc | 2024-09-30 | 12.3 M | Blackrock Inc | 2024-06-30 | 6.6 M |
Verve Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 489.36 M.Market Cap |
|
Verve Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.28) | |
| Return On Capital Employed | (0.31) | (0.33) | |
| Return On Assets | (0.27) | (0.28) | |
| Return On Equity | (0.33) | (0.32) |
Determining Verve Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Verve Therapeutics is a good buy. For example, gross profit margin measures Verve Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Verve Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Verve Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Verve Therapeutics. Check Verve Therapeutics' Beneish M Score to see the likelihood of Verve Therapeutics' management manipulating its earnings.
Evaluate Verve Therapeutics' management efficiency
Verve Therapeutics has return on total asset (ROA) of (0.2219) % which means that it has lost $0.2219 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4067) %, meaning that it created substantial loss on money invested by shareholders. Verve Therapeutics' management efficiency ratios could be used to measure how well Verve Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.28 in 2024. Return On Capital Employed is likely to drop to -0.33 in 2024. At this time, Verve Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 120.5 M in 2024, whereas Other Assets are likely to drop slightly above 3.9 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.34 | 9.81 | |
| Tangible Book Value Per Share | 9.34 | 9.81 | |
| Enterprise Value Over EBITDA | (3.51) | (3.68) | |
| Price Book Value Ratio | 1.49 | 1.57 | |
| Enterprise Value Multiple | (3.51) | (3.68) | |
| Price Fair Value | 1.49 | 1.57 | |
| Enterprise Value | 763.3 M | 1.5 B |
The strategic initiatives led by Verve Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 1.76 |
Basic technical analysis of Verve Stock
As of the 28th of November, Verve Therapeutics has the Coefficient Of Variation of 2631.63, semi deviation of 4.62, and Risk Adjusted Performance of 0.0375. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Verve Therapeutics, as well as the relationship between them. Please validate Verve Therapeutics jensen alpha and semi variance to decide if Verve Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 5.78 per share. Given that Verve Therapeutics has jensen alpha of 0.0033, we advise you to double-check Verve Therapeutics's current market performance to make sure the company can sustain itself at a future point.Verve Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Verve Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Verve Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Verve Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gv 2017 Gp, L.l.c. few days ago Disposition of 49569 shares by Gv 2017 Gp, L.l.c. of Verve Therapeutics subject to Rule 16b-3 | ||
Fiedorek Fred T. over a week ago Insider Trading | ||
Politi Jason over three months ago Disposition of tradable shares by Politi Jason of Verve Therapeutics subject to Rule 16b-3 | ||
Kathiresan Sekar over six months ago Acquisition by Kathiresan Sekar of 526000 shares of Verve Therapeutics subject to Rule 16b-3 | ||
Yeshwant Krishna over six months ago Purchase by Yeshwant Krishna of 1800000 shares of Verve Therapeutics | ||
Kathiresan Sekar over a year ago Verve Therapeutics exotic insider transaction detected | ||
Nickerson Joan over a year ago Verve Therapeutics exotic insider transaction detected | ||
Kathiresan Sekar over a year ago Acquisition by Kathiresan Sekar of 550200 shares of Verve Therapeutics subject to Rule 16b-3 |
Verve Therapeutics' Outstanding Corporate Bonds
Verve Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Verve Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Verve bonds can be classified according to their maturity, which is the date when Verve Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| VERTICAL HOLDCO GMBH Corp BondUS92537VAA89 | View | |
| VERTICAL U S Corp BondUS92537RAA77 | View | |
| US92535UAB08 Corp BondUS92535UAB08 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Verve Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Verve Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0375 | |||
| Market Risk Adjusted Performance | 0.1277 | |||
| Mean Deviation | 3.51 | |||
| Semi Deviation | 4.62 | |||
| Downside Deviation | 4.72 | |||
| Coefficient Of Variation | 2631.63 | |||
| Standard Deviation | 4.68 | |||
| Variance | 21.94 | |||
| Information Ratio | 0.0112 | |||
| Jensen Alpha | 0.0033 | |||
| Total Risk Alpha | (0.54) | |||
| Sortino Ratio | 0.0111 | |||
| Treynor Ratio | 0.1177 | |||
| Maximum Drawdown | 22.1 | |||
| Value At Risk | (9.25) | |||
| Potential Upside | 8.85 | |||
| Downside Variance | 22.27 | |||
| Semi Variance | 21.37 | |||
| Expected Short fall | (3.58) | |||
| Skewness | (0.02) | |||
| Kurtosis | 0.1739 |
| Risk Adjusted Performance | 0.0375 | |||
| Market Risk Adjusted Performance | 0.1277 | |||
| Mean Deviation | 3.51 | |||
| Semi Deviation | 4.62 | |||
| Downside Deviation | 4.72 | |||
| Coefficient Of Variation | 2631.63 | |||
| Standard Deviation | 4.68 | |||
| Variance | 21.94 | |||
| Information Ratio | 0.0112 | |||
| Jensen Alpha | 0.0033 | |||
| Total Risk Alpha | (0.54) | |||
| Sortino Ratio | 0.0111 | |||
| Treynor Ratio | 0.1177 | |||
| Maximum Drawdown | 22.1 | |||
| Value At Risk | (9.25) | |||
| Potential Upside | 8.85 | |||
| Downside Variance | 22.27 | |||
| Semi Variance | 21.37 | |||
| Expected Short fall | (3.58) | |||
| Skewness | (0.02) | |||
| Kurtosis | 0.1739 |
Consider Verve Therapeutics' intraday indicators
Verve Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Verve Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Verve Therapeutics Corporate Filings
13A | 18th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 2nd of July 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Verve Stock media impact
Far too much social signal, news, headlines, and media speculation about Verve Therapeutics that are available to investors today. That information is available publicly through Verve media outlets and privately through word of mouth or via Verve internal channels. However, regardless of the origin, that massive amount of Verve data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Verve Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Verve Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Verve Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Verve Therapeutics alpha.
Verve Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Verve Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Verve Therapeutics Corporate Management
| Jennifer Robinson | Vice Communications | Profile | |
| Kaitlin Duffy | Executive Resources | Profile | |
| Troy Lister | Chief Officer | Profile | |
| MD MPH | CoFounder Advisor | Profile | |
| Joan MBA | Chief Officer | Profile | |
| FACC MD | CoFounder | Profile |
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.